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1. Introduction 
The genome contains genetic and epigenetic information. While the genome provides the 
blueprint for the manufacture of all the proteins required to create a living thing, the 
epigenetic information provides instruction on how, where, and when the genetic 
information should be used (Robertson, 2001). The major form of epigenetic information in 
mammalian cells is DNA methylation that is the covalent addition of a methyl group to the 
5-position of cytosine, mostly within the CpG dinucleotide (Robertson, 2001). DNA 
methylation is involved in the control of gene expression, regulation of parental imprinting 
and stabilization of X chromosome inactivation as well as maintenance of the genome 
integrity. It is also implicated in the development of the immune system, cellular 
reprogramming and brain function and behaviour (Jurkowska et al., 2011). DNA 
methylation is mediated by a family of DNA methyltransferase enzymes (DNMTs). In 
mammals, three DNMTs have been identified so far in the human genome, including the 
two de novo methyltransferases (DNMT3A and DNMT3B) and the maintenance 
methyltransferase (DNMT1), which is generally the most abundant and active of the three 
(Goll and Bestor, 2005; Robertson, 2001; Yokochi and Robertson, 2002). DNMT3L is a related 
protein that has high sequence similarity with DNMT3A, but it lacks any catalytic activity 
owing to the absence of conserved catalytic residues. However, DNMT3L is required for the 
catalytic activity of DNMT3A and 3B (Cheng and Blumenthal, 2008). The protein DNMT2 
can also be found in mammalian cells. Despite the fact that the structure of DNMT2 is very 
similar to other DNMTs, its role is comparably less understood (Schaefer and Lyko, 2010). It 
has been reported that DNMT2 does not methylate DNA but instead methylates aspartic 
acid transfer RNA (tRNAAsp) (Goll et al., 2006). Recent evidence suggests that DNMT2 
activity is not limited to tRNAAsp and that DNMT2 represents a noncanonical enzyme of the 
DNMT family (Schaefer and Lyko, 2010). 
DNMT1 is responsible for duplicating patterns of DNA methylation during replication and 
is essential for mammalian development and cancer cell growth (Chen et al., 2007). These 
enzymes are key regulators of gene transcription, and their roles in carcinogenesis have 
been the subject of considerable interest over the last decade (Jones and Baylin, 2007; 
Robertson, 2001). Therefore, specific inhibition of DNA methylation is an attractive and 
novel approach for cancer therapy (Kelly et al., 2010; Lyko and Brown, 2005; Portela and 
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Esteller, 2010; Robertson, 2001). It is worth noting that DNA methylation inhibitors have 
also emerged as a promising strategy for the treatment of immunodeficiency and brain 
disorders (Miller et al., 2010; Zawia et al., 2009). 
The structure of mammalian DNMTs can be divided into two major parts, a large N-
terminal regulatory domain of variable size, which has regulatory functions, and a C-
terminal catalytic domain which is conserved in eukaryotic and prokaryotic carbon-5 
DNMTs. The N-terminal domain guides the nuclear localization of the enzymes and 
mediates their interactions with other proteins, DNA, and chromatine. The smaller C-
terminal domain harbors the active center of the enzyme and contains ten amino acids 
motifs diagnostic for all carbon-5 DNMTs (Jurkowska et al., 2011). Motifs I-III form the 
cofactor binding pocket, motif IV has the catalytic cysteine, motifs VI, VIII, and X compose 
the substrate binding site, and motifs V and VII form the target recognition domain (Sippl 
and Jung, 2009). Human DNMT1 has 1616 amino acids for which limited three-dimensional 
structural information is available. For example, just recently a crystal structure of human 
DNMT1 bound to duplex DNA containing unmethylated cytosine-guanine (CG) sites was 
published (Song et al., 2011). Further details of the structure of DNMTs and other available 
crystal structures of DNMTs are extensively reviewed elsewhere (Cheng and Blumenthal, 
2008; Lan et al., 2010; Sippl and Jung, 2009). 
The proposed mechanism of DNA cytosine-C5 methylation is summarized in Fig. 1 
(Schermelleh et al., 2005; Sippl and Jung, 2009; Vilkaitis et al., 2001). DNMT forms a complex 
with DNA, and the cytosine which will be methylated flips out from the DNA. The thiol of 
the catalytic cysteine from motif IV acts as a nucleophile that attacks the 6-position of the 
target cytosine to generate a covalent intermediate. The 5-position of the cytosine is 
activated and conducts a nucleophilic attack on the cofactor S-adenosyl-L-methionine 
(AdoMet) to form the 5-methyl covalent adduct and S-adenosyl-L-homocysteine (AdoHcy). 
The attack on the 6-position is assisted by a transient protonation of the cytosine ring at the 
endocyclic nitrogen atom N3, which is stabilized by a glutamate residue from motif VI. The 
same residue also contacts the exocyclic N4 amino group and stabilizes the flipped base. The 
carbanion may also be stabilized by resonance, where an arginine residue from motif VIII 
may participate in the stabilization of the cytosine base. The covalent complex between the 
methylated base and the DNA is resolved by deprotonation at the 5-position to generate the 
methylated cytosine and the free enzyme. 
DNA methylation inhibitors have been well characterized and tested in clinical trials (Issa 
and Kantarjian, 2009). To date, only 5-azacytidine and 5-aza-2’-deoxycytidine (Fig. 2) have 
been developed clinically. These two drugs are nucleoside analogues, which, after 
incorporation into DNA, cause covalent trapping and subsequent depletion of DNA 
methyltransferases (Schermelleh et al., 2005; Stresemann and Lyko, 2008). Aza nucleosides 
are approved by the Food and Drug Administration of the United States for the treatment of 
myelodysplastic syndrome, where they demonstrate significant, although usually transient 
improvement in patient survival and are currently being tested in many solid cancers (Issa 
et al., 2005; Schrump et al., 2006). Despite the clinical successes achieved with DNA 
methylation inhibitors, there is still need for improvement since aza nucleosides have 
relatively low specificity and are characterized by substantial cellular and clinical toxicity 
(Stresemann and Lyko, 2008). Their exact mechanism of antitumor action – demethylation of 
aberrantly silenced growth regulatory genes, induction of DNA damage, or other 
mechanism also remains unclear (Fandy et al., 2009; Issa, 2005; Palii et al., 2008). 
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Consequently, there is clear need to identify novel and more specific DNMT inhibitors that 
do not function via incorporation into DNA. 
 
 
Fig. 1. Mechanism of DNA cytosine-C5 methylation. Amino acid residue numbers are based 
on the homology model. Equivalent residue numbers in parentheses correspond to the 
crystal structure. 
There is now an increasing number of substances that are reported to inhibit DNMTs (Lyko 
and Brown, 2005). Selected DNMT inhibitors and other candidate demethylating agents are 
depicted in Fig. 2. Some of these compounds are approved drugs for other indications; i.e., 
the antihypertensive drug hydralazine (Segura-Pacheco et al., 2003), the local anaesthetic 
procaine (Villar-Garea et al., 2003), and the antiarrhythmic drug procainamide (Lee et al., 
2005a). Others like the L-tryptophan derivative RG108, NSC 14778 (Fig. 2) have been 
identified by docking-based virtual screening (Kuck et al., 2010a; Siedlecki et al., 2006). 
Several natural products have been implicated in DNA methylation inhibition. Selected 
examples are the main polyphenol compound from green tea, (-)-epigallocathechin-3-gallate 
(EGCG) (Fang et al., 2003; Lee et al., 2005b), other tea polyphenols such as catechin and 
epicatechin, and the bioflavonoids quercetin, fisetin, and myricetin. Curcumin, the major 
component of the Indian curry spice turmeric, has been reported to inhibit the DNA 
cytosine C5 methyltransferase M.SssI, an analogue of DNMT1 (Liu et al., 2009). However, 
more recent studies showed that curcumin did not cause DNA demethylation in three 
arbitrarily chosen human cancer cell lines (Medina-Franco et al., 2011). Mahanine, a plant-
derived carbazole alkaloid, and a fluorescent carbazole analogue, has been reported to 
induce the Ras-association domain family 1 (RASSF1) gene in human prostate cancer cells, 
presumably by inhibiting DNMT activity (Jagadeesh et al., 2007; Sheikh et al., 2010). 
Nanaomycin A, a quinone antibiotic isolated from a culture of Streptomyces, has been 
described as the first non S-adenosyl-L-homocysteine (AdoHcy/SAH) analogue acting as a 
DNMT3B-selective inhibitor that induces genomic demethylation. Nanaomycin A treatment 
reduced the global methylation levels in three cell lines and reactivated transcription of the 
RASSF1A tumor suppressor gene (Kuck et al., 2010b). These and several other natural 
products as putative demethylating agents are extensively reviewed elsewhere (Gilbert and 
Liu, 2010; Hauser and Jung, 2008; Li and Tollefsbol, 2010; Medina-Franco and Caulfield, 
2011). While the substantial number of recent reports may suggest that many natural 
products inhibit DNA methylation, it should be noted that only a few reports provide 
compelling evidence for DNMT inhibition in biochemical and in cellular assays. As such, it 
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remains possible that many of these compounds have an indirect and fortuitous effect on 
DNA methylation, but do not show a pharmacologically relevant activity that can be 
developed further for therapeutic purposes (Medina-Franco et al., 2011). 
 
 
Fig. 2. Chemical structures of selected DNA methyltransferase inhibitors and other 
compounds with putative demethylating activity. 
Until now most compounds associated with DNA methylation inhibition have been 
identified fortuitously. Remarkable exceptions are RG108 and 5,5’-methylenedisalicylic acid 
(NSC 14778) that were identified by computational screening followed by experimental 
evaluation (Kuck et al., 2010a; Siedlecki et al., 2006). In order to accelerate the discovery and 
optimization of new DNMT inhibitors, rational approaches are increasingly being used. To 
this end, in silico studies have significantly helped to understand the structure and function 
of DNMTs and the mechanism of DNMT inhibition (Medina-Franco and Caulfield, 2011). 
This chapter focuses on the different strategies ongoing in our and other research groups for 
the discovery and optimization of inhibitors of DNMTs with particular emphasis on in silico 
screening (section two) and in silico design (section three). 
2. In silico screening of compound collections to identify novel inhibitors 
In silico screening, also called in the literature, computational or virtual screening, consists of 
the computational evaluation of databases aiming to select a small number of reliable and 
experimentally testable candidate compounds that have a high probability of being active 
(Muegge, 2008; Shoichet, 2004). In silico screening is one of the most common rational 
approaches to guide the identification of new hits from large compound libraries. Hit 
identification using this approach requires several interactive steps that include (1) the 
compound collection, (2) the computational methods used for screening, and (3) the analysis 
of the output (López-Vallejo et al., 2011).  
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2.1 Screening databases 
A number of compound databases from different sources can be used in in silico screening. 
These libraries may contain existing or hypothetical; i.e., virtual compounds. Libraries of 
existing compounds may be proprietary; e.g., in-house libraries, commercial, or public. The 
sources of screening libraries, with emphasis on libraries in the public domain, have been 
reviewed (Bender, 2010; Scior et al., 2007). Currently, the ZINC database is one of the most 
used libraries (Irwin and Shoichet, 2005). The type of screening library utilized should be 
closely associated with the objective of the particular screening campaign (Shelat and Guy, 
2007). Chemically diverse libraries are particular attractive for identifying novel scaffolds for 
new or relatively unexplored targets such as DNMTs. If the goal is lead optimization, e.g., 
optimize the activity of known DNMT inhibitors (Fig. 2), focused libraries or collections 
with high inter-molecular similarity (highly dense libraries) are an attractive source. 
2.1.1 Natural product databases 
The presence of DNMT inhibitors in dietary products and commonly used herbal remedies 
(Gilbert and Liu, 2010; Hauser and Jung, 2008; Li and Tollefsbol, 2010) demonstrates the 
feasibility of identifying additional inhibitors of natural origin. Natural products have 
unique characteristics attractive for drug discovery. For example, the chemical structures of 
natural products are, in general, different from the chemical structures of synthetic 
compounds occupying different areas of chemical space (Ganesan, 2008; Medina-Franco et 
al., 2008; Singh et al., 2009b). In addition, natural products may be drug candidates 
themselves or may be the starting point for an optimization program (Ganesan, 2008; 
Hauser and Jung, 2008). Indeed several natural products are bioavailable, and the rationale 
of these observations has been recently provided (Ganesan, 2008). Fig. 3 shows a visual 
representation of the chemical space of natural products, drugs, and DNMT inhibitors. To 
compare the chemical space, a subset of 1,000 compounds was randomly selected from each 
database. The visual representation was obtained with principal component analysis (PCA) 
of the similarity matrix of the databases computed using Molecular ACCess System 
(MACCS) keys (166 bits) and the Tanimoto coefficient (Maggiora and Shanmugasundaram, 
2011). The first three principal components are displayed in Fig. 3 and account for 79% of 
the variance. This figure clearly shows that most of the DNMT inhibitors, e.g., nucleoside 
analogues, RG108, RG108-1, procaine, procainamide, SG1027, and hydralazine, share the 
same chemical space of drugs. This observation is expected from inhibitors such as procaine, 
procainamide, and hydralazine. In contrast, NSC14778 and DNMT inhibitors from natural 
origin, EGCG and curcumin, are in a less-dense populated area of the chemical space of 
drugs. These compounds are characterized by containing one or more hydroxyl groups. Fig. 
3b shows that most of the compounds in the natural product database also occupy this 
second region. Before conducting virtual and experimental screening, it is feasible to filter 
out natural products with potential toxicity issues using drug- or lead-like filters (Charifson 
and Walters, 2002). 
2.1.2 Combinatorial libraries 
Combinatorial libraries, either existing or virtual, are important sources of compound 
collections that can be used for in silico screening (López-Vallejo et al., 2011). Advances in 
synthetic approaches can generate libraries from libraries, target-oriented libraries, and 
diversity-oriented libraries which explore the chemical space in different ways (López-Vallejo 
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et al., 2011) and can be used in lead optimization or hit-identification, depending on the 
goals of the screening campaign. 
 
 
Fig. 3. Comparison of 486 natural products (black triangles), 1,000 drugs (red triangles), and 
14 DNMT1 inhibitors (blue spheres). Depiction of a visual representation of the chemical 
space obtained by PCA of the similarity matrix computed using MACCS keys and Tanimoto 
similarity. The first three PCs account for 79% of the variance. (a) Comparison of drugs and 
DNMT1 inhibitors. (b) Comparison of drugs, natural products, and DNMT inhibitors. 
2.2 Development and validation of computational approaches 
In silico screening can be divided into two general strategies: ligand-based and structure-
based (Medina-Franco et al., 2006; Ooms, 2000). Ligand-based approaches use the structural 
information and biological activity data from a set of known active compounds to select 
promising candidates for experimental screening. When the three-dimensional structure of 
the target is known, structure-based methods can be used. Three-dimensional structure 
information of the target is usually obtained from X-ray crystallography or nuclear magnetic 
resonance. In the absence of three-dimensional structural information of the receptor, 
homology models have been successfully used (Grant, 2009; Villoutreix et al., 2009). Perhaps 
the most common structure-based approach is molecular docking. Docking aims to find the 
best position and orientation of a molecule within a binding site and gives a score for each 
docked pose (Hernández-Campos et al., 2010; Kitchen et al., 2004; Villoutreix et al., 2009). 
Ligand- and structure-based methods can be combined if information for both the 
experimentally active compounds and the three-dimensional structure of the target are 
available (Sperandio et al., 2008). The selection of a particular method is generally based on 
the goal of the project, the information available for the system, and the computational 
resources available. For structure-based and ligand-based methods, it is highly advisable to 
validate the virtual screening protocol prior to the selection of compounds for experimental 
testing. However, the experimental results of the tested candidates will provide full 
validation of the virtual screening approach. 
2.2.1 Structure-based screening 
Structure-based screening for novel DNMT inhibitors performed so far has been conducted 
with homology models of the catalytic domain (Kuck et al., 2010a; Siedlecki et al., 2006). The 
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construction of useful homology models has been facilitated by the extensive conservation 
of the catalytic domain of DNMTs (Kumar et al., 1994). Crystal structures of other 
methyltransferases such as bacterial DNA cytosine C5 methyltransferase from Haemophilus 
hemolyticus (M.HhaI), bacterial cytosine C5 methyltransferase M.HaeIII, and the human 
DNMT2 (Siedlecki et al., 2003; Yoo and Medina-Franco, 2011) have been used as templates 
(Medina-Franco and Caulfield, 2011). 
We have recently developed two homology models of the catalytic domain of DNMT1. In 
one model (Yoo and Medina-Franco, 2011), the crystal structures of the DNMTs M.HhaI, 
M.HaeIII, and DNMT2 were used as templates. The first structure is a ternary complex of 
M.HhaI, S-adenosyl methionine (AdoMet), and DNA containing flipped 4’-thio-2’-
deoxcytidine with partial methylation at C5. The crystal structure of M.HaeIII is bound 
covalently to DNA. In this complex, the substrate cytosine is extruded from the DNA and it 
is inserted into the active site. The structure of human DNMT2 complexed with S-adenosyl-
L-homocysteine (AdoHcy/SAH) has high similarities to methyltransferases of both 
prokaryotes and eukaryotes. A second homology model was developed using only the 
structure of M.HhaI as template. Both models contain DNA and the conserved residues 
which are involved in the catalytic mechanism. The target cytosine which is flipped out of 
the embedded DNA is inserted into the active site. The catalytic loop containing the catalytic 
cysteine is located above the cytosine as an active site “lid”. The target cytosine lies between 
the nucleophile cysteine residue (Cys1225) and the sulfur atom of AdoHcy. The distance of 
cytosine C6 to the sulfur atom of Cys1225 is 3.3 Å. The cytosine C5 atom is 3.0 Å away from 
the sulfur atom of AdoHcy. In the reactive state of Cys1225, the distance between Oε1 of 
Glu1265 and N3 of cytidine is 2.8 Å, where the N3 atom is proposed to be protonated 
making a hydrogen bond with the acidic side chain of Glu1265. In addition, the N3 
protonated form of cytosine can make hydrogen bonds with Arg1311 and Pro1223. These 
key interactions in the catalytic site are commonly observed in both homology models. More 
specifically, in the first homology model, the α-phosphate backbone and 3‘-OH of the sugar 
moiety of deoxycytidine make a hydrogen bond network with Arg1311, Arg1461, Ser1229, 
Gly1230, and Gln1396; in the second model, the interactions are observed with the following 
residues: Gln1226, Ser1229, Gly1230, Arg1268, and Arg1310. 
Fig. 4 shows a superimposition of the first homology model of the catalytic site of hDNMT1 
(Yoo and Medina-Franco, 2011) with the recently published crystal structure of 
unmethylated human DNMT1 (Song et al., 2011). The catalytic cores of their 
methyltransferase domains have similar features, but unmethylated DNA in the 
crystallographic structure is positioned further away from the active site. In the crystal 
structure of the human DNMT complex, the key amino acid residues Glu1265 and Arg1311 
are positioned in very similar place. In contrast, the catalytic loop adopts a different 
conformation with respect to the homology model. The catalytic loop has an open 
conformation, and the catalytic cysteine is far from the binding site, e.g., the distance of 
superimposed cytosine C6 to the sulfur atom of Cys1225 is 9.5 Å. Taken together, the 
structural characterization of the catalytic site supports that our homology model is in full 
agreement with the proposed catalytic mechanism of DNA methylation.  
In silico screening has been successfully used to identify novel small molecule inhibitors of 
DNMT1. In one study, 1990 compounds in the Diversity Set available from the National 
Cancer Institute were the starting point of a screening using docking with a validated 
homology model of human DNMT1. Compounds with undesirable size, hydrophobicity, 
and uncommon atom types were filtered out. Two of the top scoring compounds were 
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tested experimentally showing activity both in vitro and in vivo, probably by binding into the 
DNMT1 catalytic pocket (Siedlecki et al., 2006). In that work, RG108 (Fig. 2) showed an IC50 
= 0.60 M with M.SssI (Siedlecki et al., 2006). Additional characterization showed that this 
L-tryptophan derivative did not cause covalent enzyme trapping and that the carboxylate 
group plays an essential role in the binding with the enzyme since the analogue without this 
moiety is inactive (Brueckner et al., 2005). 
 
 
Fig. 4. (a) Superposition of the homology model (green) of the catalytic domain of human 
DNMT1 with the crystallographic structure (pink) of the unmethylated human DNMT1. The 
catalytic loops are marked with arrows. AdoHcy and the flipped cytosine in the homology 
model are shown in space-filling view. (b) Binding model of deoxycytidine (black) with key 
amino acid residues of homology model (carbon atoms in green) and crystal structure 
(carbon atoms in pink). Hydrogen bonding interactions are represented by dotted lines.  
In a follow-up study, our group screened a larger set of the National Cancer Institute 
database containing more than 260,000 compounds (Kuck et al., 2010a). In order to focus the 
screening on compounds that could be promising for further development, we selected a 
subset of approximately 65,000 lead-like molecules (Charifson and Walters, 2002). The lead-
like set was further filtered using a high-throughput in silico screening. As part of the 
screening, three docking programs were used. Favorable docking scores from all three 
docking approaches were combined to create a total of 24 consensus compounds. Of the 24 
molecules that were identified, thirteen were obtained for experimental testing. Seven out of 
the thirteen consensus hits had detectable DNMT1 inhibitory activity in biochemical assays. 
Further experimental characterization of active compounds showed that six out of the seven 
inhibitors appeared selective for DNMT1. The methylenedisalicylic acid derivative, NSC 
14778 (Fig. 2), showed an IC50 = 92 M with DNMT1 and an IC50 = 17 M with DNMT3B. 
The observed potency was comparably low for most test compounds, which was partially 
attributed to the high amount of protein used in the biochemical assay. In fact, it is well-
known that DNMTs are weak catalysts and are difficult to assay (Hemeon et al., (2011 -
ASAP)). Despite the low potency, the in silico screening was successful in that it identified 
diverse scaffolds that were not previously reported for DNMT inhibitors. The new scaffolds 
represent excellent candidates for optimizing their inhibitory activity and selectivity. 
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Fig. 5. (a) Structure-based pharmacophore model proposed for human DNMT1 inhibitors. 
Red sphere: negative ionizable, pink sphere: hydrogen bond acceptor, blue sphere: hydrogen 
bond donors, and orange ring: aromatic ring. Selected amino acid residues in the catalytic site 
of homology model are schematically depicted for reference. Comparison between the 
binding mode and pharmacophore hypothesis for representative DNMT inhibitors, (b) 5-
azacytidine, (c) NSC14778, (d) hydralazine, and (e) RG108.  
Recently, our group developed a structure-based pharmacophore hypothesis for inhibitors 
of DNMT1 (Yoo and Medina-Franco, 2011). Using the energy optimized hypothesis, ‘e-
pharmacophore’ method (Salam et al., 2009) the pharmacophore model was developed 
based on the scores and predicted binding modes of 14 known DNMT1 inhibitors docked 
with a homology model of DNMT1. Fig. 5a shows the pharmacophore model for the 14 
DNMT1 inhibitors. The model contains five features which represent the most important 
interactions of the inhibitors with the catalytic domain. The energetic value assigned to each 
pharmacophoric feature is displayed in the figure. Nearby amino acids are schematically 
depicted for reference. The best-scoring feature is a negative charge which is close to the 
side chains of Ser1229, Gly1230, and Arg1311. The second most favorable feature is an 
acceptor site that is in close proximity with the side chains of Arg1311 and Arg1461. The 
third ranked features are an aromatic ring that stabilizes the binding conformation of 
ligands between AdoHcy and Cys1225, and a donor site that is close to the side chain of 
Gln1396. The fifth-ranked feature is a donor site that is nearby the side chain of Glu1265 
which is a residue implicated in the methylation mechanism. Fig. 5b shows the alignment of 
representative DNMT inhibitors to the pharmacophore hypothesis. It remains to evaluate 
the performance of the pharmacophore model in prospective in silico screening. 
2.2.2 Ligand-based screening 
Ligand-based screening can be performed as an alternative approach when the relevant 
crystal structures are not available on the molecular target. Ligand-based approaches 
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include similarity searching, substructure, clustering, quantitative structure-activity 
relationships (QSAR), pharmacophore-, or three-dimensional shape matching techniques 
(Villoutreix et al., 2007). Several ligand-based methods, including similarity searching and 
QSAR, can roughly be divided into two- or three-dimensional approaches. Ligand-based 
virtual screening may be applied even if a single known-ligand has been identified through 
similarity-based screening. Interestingly, although many more successful structure-based 
than ligand-based virtual screening applications are reported to date, recent reviews 
indicate that the potency of hits identified by ligand-based approaches is on average 
considerably higher than for structure-based methods (Ripphausen et al., 2011; Ripphausen 
et al., 2010). 
If multiple active compounds are known, it is possible to apply QSAR using two- or three-
dimensional information of the ligands. One of the main goals of QSAR is to derive 
statistical models that can be used to predict the activity of molecules not previously tested 
in the biological assay. Despite the fact that QSAR is a valuable tool, there are potential 
pitfalls to develop predictive QSAR models (Scior et al., 2009). A major pitfall can occur 
when the compounds were assayed using different experimental conditions. Other major 
pitfall is due to the presence of “activity cliffs,” i.e., compounds with very high structural 
similarity but very different biological activity (Maggiora, 2006). Activity cliffs give rise to 
QSAR with poor predictive ability (Guha and Van Drie, 2008). 
3. In silico design and optimization of established inhibitors 
Concerns about severe toxicity of nucleoside analogues have strongly encouraged not only 
identifying novel DNMT inhibitors but also developing further established non-nucleoside 
inhibitors. To this end, medicinal chemistry approaches, either alone or in combination with 
in silico strategies, are being pursued. 
3.1 Optimization of RG108, procaine, and mahanine 
As mentioned above, procaine, a local anesthetic drug, and procainamide, a drug for the 
treatment of cardiac arrhythmias, have been reported as inhibitors of DNA methylation (Fig. 
2). In a recent report, constrained analogues of procaine were synthesized and tested for 
their inhibition against DNMT1 (Castellano et al., 2008). Procaine as a lead structure was 
modified to partially reduce the high flexibility which can have a detrimental effect for 
drug-likeness. The most potent inhibitor in an in vitro methylation assay also showed 
demethylation activity in HL60 human myeloid leukemia cells, and it was suggested as a 
lead compound for further studies (Castellano et al., 2008). 
In a separate work, a series of maleimide derivatives of RG108 were reported (Suzuki et al., 
2010). In that work, design, chemical synthesis, inhibitory activity assays, and automated 
docking methods were used. The most active compound of the series was RG108-1 (Fig. 2). 
A binding model of RG108-1 with the crystal structure of bacterial M.HhaI suggested that 
this compound could be a covalent blocker of the catalytic cysteine. A more recent 
molecular modelling study using a model of human DNMT1 (Yoo and Medina-Franco, 
2011) supported this hypothesis. Interestingly, in the model obtained with human DNMT, 
the maleimide moiety of RG108-1 interacts with Arg1311, Arg1461, and lies next to Cys1225, 
where the conjugate addition of the thiol group of the catalytic cysteine to the maleimide 
can occur. In addition, the carboxylate anion of RG108-1 overlaps with that of RG108 and 
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has the same interaction with Arg1311, Ser1229, and Gly1230 (Yoo and Medina-Franco, 
2011). 
The natural product mahanine (Fig. 2) has the ability to restore RASSF1A expression, and it 
is a potent inhibitor of androgen dependent (LNCaP) and androgen independent (PC-3) 
human prostate cancer cell proliferation (Jagadeesh et al., 2007). The antiproliferative 
activity of mahanine is associated with inhibition of the DNMT activity. Recently, 
fluorescent carbazole analogues of mahanine were designed and synthesized to find a novel 
and more potent small molecule with a mechanistic profile similar to that of the parent 
compound. Compound ‘9’ in Fig. 2 inhibited human prostate cancer cell proliferation at 1.5 
µM and also showed DNMT inhibition activity without the cytotoxic effects seen with 
mahanine treatment. Inhibition of DNMT was proposed as the event leading to the 
restoration of RASSF1A expression (Sheikh et al., 2010). 
3.2 Structure-based optimization of hydralazine 
Hydralazine, a potent arterial vasodilator, has been used for the management of 
hypertensive disorders and heart failure. Using a drug repurposing strategy (Duenas-
Gonzalez et al., 2008), clinical trials have demonstrated the antitumor effect of the 
combination of hydralazine with valporic acid (a histone deacetylase inhibitor). Hydralazine 
and procainamide were first reported to have DNA methylation inhibition effect in 1988. 
Despite the fact that numerous studies were conducted with hydralazine, its molecular 
mechanism has remained unknown. In order to help understand the activity of hydralazine 
at the molecular level, we developed a binding mode of this compound with a validated 
homology model of the catalytic domain of DNMT1 using docking and molecular dynamics 
(Singh et al., 2009a; Yoo and Medina-Franco, 2011).  
In molecular modeling studies, hydralazine showed similar interactions within the binding 
pocket as nucleoside analogues including a complex network of hydrogen bonds with 
arginine and glutamic acid residues that play a major role in the mechanism of DNA 
methylation (Yoo and Medina-Franco, 2011). Fig. 6 shows the comparison of the binding 
modes of hydralazine with 5-azacytidine. The amino group of hydralazine matched well 
with the amino group of 5-azacytidine, and it is capable of making hydrogen bonds with 
Glu1265 and Pro1223. The nitrogen of the phthalazine ring overlapped with the carbonyl 
oxygen of 5-azacytidine and formed hydrogen bonds with Arg1311 and Arg1461. We also 
identified that the small structure of hydralazine could not occupy the site of the sugar ring 
and phosphate backbone of nucleoside analogues. This result also suggests that hydralazine 
can be substituted at the C4 position to yield analogues with enhanced affinity with the 
enzyme. In contrast, there is a small empty pocket nearby the carbocyclic aromatic ring of 
hydralazine (C5-C8) that can be occupied by a substituent (Yoo and Medina-Franco, 2011). 
The molecule shown in Fig. 6 was designed based on the structure and binding mode of 
hydralazine. Molecular modeling indicates that the addition of a phenyl group in the C4 
position of hydralazine improves the calculated binding affinity with DNMT1. Moreover, 
adding polar substituents at various positions of the phenyl group can provide additional 
favorable interactions with the catalytic site. Also based on our molecular modeling 
analysis, the binding affinity is expected to increase by the addition of polar groups to the 
carbocyclic aromatic ring of phthalazine. It is expected that new compounds with increased 
calculated affinity with the enzyme will show increased potency in the DNMT1 enzyme 
inhibition assays. 
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Fig. 6. Design of analogues of hydralazine. (a) comparison of the binding modes of 
hydralazine (carbon atoms in pink) with 5-azacytidine (carbon atoms in green)  
(b) structure-guided design of a representative hydralazine analogue (carbon atoms in 
green). 
3.3 Design of focused combinatorial libraries 
Computer-assisted combinatorial library design is a powerful tool frequently used in the 
discovery and optimization of new lead compounds. Molecular diversity has played a 
critical role in designing combinatorial libraries for screening (Tommasi and Cornella, 2006; 
Zheng and Johnson, 2008). However, the core chemical scaffolds of some currently used 
diverse libraries might be inadequate to provide drug-like compounds for new targets. 
Library design based on bioisosteric replacement or scaffold hopping methods can be used 
as an alternative to diversity oriented synthesis. Bioisostere searching involves swapping 
functional groups of a molecule with other functional groups that have similar biological 
properties. Scaffold hopping is an approach to discover structurally novel compounds 
starting from known active compounds by modifying the central core structure of the 
molecule (Brown and Jacoby, 2006). Scaffold hopping is an important drug design strategy 
to develop novel molecules with potent activity, altered physicochemical attributes, and 
Absorption, Distribution, Metabolism, Excretion and Toxicity –ADMET- properties. An 
example of application is phosphodiesterase 5 inhibitors for the treatment of erectile 
dysfunction. Sildenafil and vardenafil represent a case of heteroaromatic core scaffolds 
hopping with a small change in the scaffold (Jordan and Roughley, 2009). In contrast, 
tadalafil has a very different core scaffold, but it has the same biological activity. 
Computational design of focused libraries or compounds designed using any other strategy 
has to be in agreement with the experimental synthetic feasibility of the compounds 
proposed. Ideally, synthetic routes should follow short and easy steps. 
Fig. 7 shows additional hydralazine analogues that have been proposed based on the 
knowledge gained in our previous molecular modeling studies of DNMT inhibitors. Starting 
from the 1-hydrazinyl-4-phenylphthalazine, polar groups are introduced into the 
carbocyclic aromatic ring of phthalazine. Based on molecular modeling analysis, 
substitution at ortho-, meta-, and para- position of the phenyl group with e.g., carboxyl, 
cyanide, and acetyl, showed a significant improvement in the calculated binding of the new 
compounds with DNMT1. A carboxyl group introduced into the ortho position plays a key 
role to make hydrogen bonds with Ser1229 or Gly1230. In contrast, substitution at C8 
position of the phthalazine did not fit well into the catalytic site because of the narrow 
pocket size. Addition of polar groups to other positions slightly increases the predicted 
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binding affinity with the enzyme. Further chemical modifications to the structures of the 




Fig. 7. Binding mode of hydralazine analogues (carbon atoms in pink) designed by scaffold 
hopping. The carbon atoms of new core scaffold are in green. Analogues with (a) ortho-
carboxylate substitution and (b) meta-acetyl substitution on the phenyl moiety. 
3.4 Characterization of structure-activity relationships 
Currently, DNMT inhibitors have been screened in different assays using different 
conditions, and QSAR studies may not be reliable. However, once quality activity data has 
been gathered for several compounds assayed under comparable experimental conditions, it 
is feasible to conduct structure-activity relationships (SAR) of the compounds tested. When 
there is a significant amount of data, for example, activity data for more than 100 or 200 
compounds, systematic analysis of the SAR can be performed via chemoinformatic 
approaches using the concept of “activity landscape modelling” (Wawer et al., 2010). The 
goal of activity landscape modeling of molecular data sets is to help rationalize the 
underlying SAR identifying key compounds and structural features for further exploration. 
The concept of activity landscape is strongly associated with the basic relationships between 
molecular structure and biological activity. While predictive SAR methods, such as 
pharmacophore modelling and traditional QSAR, focus on specific molecular descriptors or 
arrangements of substructures or functional groups associated with activity, descriptive 
activity landscape models rely on the “similarity property principle,” i.e., similar structures 
should have similar biological properties (Bender and Glen, 2004; Maggiora and 
Shanmugasundaram, 2011) and employ whole-molecular similarity measures (Wawer et al., 
2010). Systematic approaches to model activity landscapes and to detect “activity cliffs” 
using multiple representations are published elsewhere (Medina-Franco et al., 2009; Pérez-
Villanueva et al., 2010; Pérez-Villanueva et al., 2011). 
4. Conclusion 
DNA methyltransferases are promising epigenetic targets for the treatment of cancer and 
other diseases. Clinical data demonstrates the potential of DNMT inhibitors for the 
therapeutic treatment of cancer. This is evidenced by the two DNMT inhibitors approved by 
the Food and Drug Administration of the United States for the treatment of patients with 
high-risk myelodysplastic syndrome. However, current approved drugs are nucleoside 
analogues that are not specific and still present issues such as cellular and clinical toxicity. A 
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wide range of computational approaches are being used to assist in the discovery and 
development of novel DNMT inhibitors. Molecular docking, pharmacophore modelling and 
molecular dynamics have been used to better understand the mechanism of action of 
established DNMT inhibitors; in silico screening of large compound libraries followed by 
experimental testing has been successful in identifying non-nucleoside inhibitors with novel 
chemical scaffolds; structure-based design is being used to guide the optimization of 
inhibitors such as hydralazine. Homology models of the catalytic domain of DNMT1 has 
played an important role to conduct the computational approaches that rely on the three 
dimensional structure of the target. It is expected that the recently published crystal 
structure of human DNMT1 bound to duplex DNA containing unmethylated CG sites will 
be the starting point of future structure-based studies with inhibitors of DNA methylation. It 
is also anticipated that the synergistic combination of computational approaches with 
combinatorial chemistry, and the systematic in silico and experimental screening of natural 
products will boost the discovery and optimization of inhibitors of DNMT for cancer 
therapy. 
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